\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[greek,ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Biofield Energy Treatment Based Test Formulation as a Novel and
Efficient Approach on Various Biomarkers in human Bones, Heart, Liver,
Lungs, and Brain Cells}



\author[1]{Streicher LN}%
\author[1]{Mahendra Kumar Trivedi}%
\author[1]{Alice Branton}%
\author[1]{Dahryn Trivedi}%
\author[1]{Gopal Nayak}%
\author[1]{Mayank Gangwar}%
\author[1]{Snehasis Jana}%
\affil[1]{Affiliation not available}%


\vspace{-1em}



  
  \date{May 17, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
Multiple organ dysfunction syndromes (MODS) are one of the common
reasons for increased mortality rate against healthcare services. The
present experiment aimed to determine the impact of the Biofield Energy
Treated test formulation on the function of vital organs such as bones,
heart, liver, lungs, and brain using standard activity parameters in
specific cell-based assays. The test formulation and cells medium was
divided into two parts; one untreated (UT) and other part received the
Biofield Energy Treatment remotely by a renowned Biofield Energy Healer,
Laura Nelson Streicher, and USA and were labeled as the Biofield Energy
Treated (BT) test formulation/media. The test formulation was tested
against various activities using cell line assay. The test formulation
was tested for cell viability, and the results showed that the test
formulation was found non-toxic against all the cell lines at the tested
concentrations. Cytoprotective activity among the experimental groups
showed a significant improved activity by 156.9\% at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL in UT-
medium (Med) + BT - test item/formulation (TI) group in human cardiac
fibroblasts cells (HCF) cells, while 94.5\% at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL in the UT-Med
+ BT-TI group in human hepatoma cells (HepG2), and 92.4\% at 63.75 \selectlanguage{greek}μ\selectlanguage{english}g/mL
in the BT-Med + BT-TI group as compared with the untreated test group in
adenocarcinomic human alveolar basal epithelial cells (A549) cells as
compared with the untreated test group. Alkaline phosphatase (ALP)
activity in MG-63 cells was significantly increased by 80.2\% and 93.5\%
at 10 and 50 \selectlanguage{greek}μ\selectlanguage{english}g/mL respectively in the UT-Med + BT-TI group, while in
Ishikawa cells showed maximum increased ALP activity by 51.5\% at 1
\selectlanguage{greek}μ\selectlanguage{english}g/mL in UT-Med + BT-TI group as compared to the untreated group. The
percent protection of HCF (heart) cells (decreased of lactate
dehydrogenase-LDH activity) was significantly increased by 156.9\% and
18.3\% at 1 and 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL concentrations respectively, in UT-Med + BT-TI
group, while BT-Med + UT-TI group showed increased protection by 24.5\%
and 17.7\% at10 and 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL respectively, and 67.1\%, 32.2\%, 47.7\%,
and 73.1\% improved cellular protection 1, 10, 25.5, and 63.75 \selectlanguage{greek}μ\selectlanguage{english}g/mL
respectively, in BT-Med + BT-TI group as compared to the untreated test
group. Alanine amino transferase (ALT) in terms of percent protection of
HepG2 (liver) cells (decreased of ALT activity) was reported by 93.1\%
and 64.1\% at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL in the UT-Med + BT-TI and BT-Med + UT-TI groups,
respectively as compared to the untreated group. Cellular protection of
A549 (lungs) cells (increased of superoxide dismutase-SOD activity) in
terms of percentage was increased by 20.6\% (at 0.1 \selectlanguage{greek}μ\selectlanguage{english}g/mL) and 6.9\% (at
10 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively
as compared to untreated group. Serotonin level was significantly
increased by 59.3\% (at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 55.6\% (at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 100.1\% (at
0.1 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BTTI, BT-Med + UT-TI, and BT-Med + BT-TI
groups, respectively compared to untreated in human neuroblastoma cells
(SHSY5Y). However, the relative quantification (RQ) of vitamin D
receptor (VDR) was significantly increased by 150.6\% (at 50 \selectlanguage{greek}μ\selectlanguage{english}g/mL),
380.1\% (at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 148.1\% (at 50 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BT-TI,
BT-Med + UT-TI, and BT-Med + BTTI groups, respectively as compared to
the untreated in MG-63 cells. In conclusion, test formulation would be
significantly useful for multiple organ health and improve overall
health of bones, heart, liver, lungs, and brain after treatment with the
Biofield Energy treated test formulation (The Trivedi Effect\selectlanguage{ngerman}®). As a
complementary and alternative therapy, Biofield Energy approach can be
used against coronary artery disease, arrhythmias, congenital heart
disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis,
asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.%
\end{abstract}\selectlanguage{ngerman}%



\sloppy


\textbf{Journal Name:}~Open Access Journal of Pharmaceutical Research
(OAJPR)

\textbf{Date of Publication:}~05-07-2019

\textbf{ISSN:}~2574-7797

\textbf{Volume:}~3

\textbf{Issue:}~3

\textbf{\textbf{Journal Web
URL:}}~\url{https://medwinpublishers.com/OAJPR/volume.php?volumeId=203\&issueId=744}

\textbf{~\textbf{Journal PDF
URL:}}~\url{https://medwinpublishers.com/OAJPR/OAJPR16000180.pdf}

\textbf{Publisher:}~Medwin

\textbf{Keywords:}~The Trivedi Effect\selectlanguage{ngerman}®; Biofield energy treatment;
Cardiac health; Liver health; Lungs health; VDR receptors; Brain health;
Bone health

\textbf{Citation:}~Streicher LN, et al. Biofield Energy Treatment Based
Test Formulation as a

Novel and Efficient Approach on Various Biomarkers in human Bones,

Heart, Liver, Lungs, and Brain Cells. Pharm Res 2019, 3(3): 000180.

\selectlanguage{english}
\FloatBarrier
\end{document}

